Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases
-
Published:2024-02-05
Issue:3
Volume:25
Page:1933
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Abrami Michela1, Biasin Alice1ORCID, Tescione Fabiana2ORCID, Tierno Domenico3, Dapas Barbara4, Carbone Annalucia5, Grassi Gabriele3ORCID, Conese Massimo5ORCID, Di Gioia Sante5ORCID, Larobina Domenico2ORCID, Grassi Mario1ORCID
Affiliation:
1. Department of Engineering and Architecture, University of Trieste, Via Valerio 6/A, I-34127 Trieste, Italy 2. Institute of Polymers, Composites and Biomaterials, National Research Council of Italy, P.le E. Fermi 1, I-80055 Portici, Italy 3. Clinical Department of Medical, Surgical and Health Sciences, Cattinara University Hospital, University of Trieste, Strada di Fiume 447, I-34149 Trieste, Italy 4. Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, I-34127 Trieste, Italy 5. Department of Clinical and Experimental Medicine, University of Foggia, Via Napoli 121, I-71122 Foggia, Italy
Abstract
The respiratory mucus, a viscoelastic gel, effectuates a primary line of the airway defense when operated by the mucociliary clearance. In chronic respiratory diseases (CRDs), such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF), the mucus is overproduced and its solid content augments, changing its structure and viscoelastic properties and determining a derangement of essential defense mechanisms against opportunistic microbial (virus and bacteria) pathogens. This ensues in damaging of the airways, leading to a vicious cycle of obstruction and infection responsible for the harsh clinical evolution of these CRDs. Here, we review the essential features of normal and pathological mucus (i.e., sputum in CF, COPD, and asthma), i.e., mucin content, structure (mesh size), micro/macro-rheology, pH, and osmotic pressure, ending with the awareness that sputum biomarkers (mucins, inflammatory proteins and peptides, and metabolites) might serve to indicate acute exacerbation and response to therapies. There are some indications that old and novel treatments may change the structure, viscoelastic properties, and biomarker content of sputum; however, a wealth of work is still needed to embrace these measures as correlates of disease severity in association with (or even as substitutes of) pulmonary functional tests.
Funder
European Union–Next Generation EU
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference327 articles.
1. GBD 2019 Chronic Respiratory Diseases Collaborators (2023). Global burden of chronic respiratory diseases and risk factors, 1990–2019: An update from the Global Burden of Disease Study 2019. EClinicalMedicine, 59, 101936. 2. World Health Organization (2023, October 29). Chronic Obstructive Pulmonary Disease (COPD). 16 March 2023. Available online: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). 3. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019;Diseases;Lancet,2020 4. World Health Organization (2023, October 29). Asthma. Available online: https://www.who.int/news-room/fact-sheets/detail/asthma. 5. Scotet, V., L’Hostis, C., and Ferec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.
|
|